
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.
Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.
Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.
Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.
Published: December 10th 2024 | Updated:
Published: December 11th 2024 | Updated:
Published: December 16th 2024 | Updated:
Published: December 17th 2024 | Updated:
Published: December 12th 2024 | Updated: